Outcomes and patterns of recurrence of robot‑assisted or laparoscopic radical hysterectomy in early‑stage cervical cancer

The present study aimed to evaluate the surgical outcomes and prognosis of minimally invasive surgery (MIS), including robot-assisted radical hysterectomy (RARH) and laparoscopic radical hysterectomy (LRH), and open radical hysterectomy (ORH) for the treatment of early stage cervical cancer. A total of 43 patients were enrolled into the ORH group, 14 patients into the LRH group and 21 patients into the RARH group, and the patients were followed up for ≥3 years. Age, body mass index, International Federation of Gynecology and Obstetrics 2008 stage, histology, tumor size, lymphovascular space invasion, lymph node metastasis, number of dissected lymph nodes, operative duration, estimated blood loss, hospitalization duration and complications were reviewed. On follow-up, 16.3% of relapses (7/43) and 11.6% of deaths (5/43) occurred in the ORH group. In the LRH group, 14.3% of patients relapsed (2/14) and no deaths were reported; however, in the RARH group, 33.3% of patients relapsed and 9.5% died (2/21). In patients treated with RARH, >50% of recurrences occurred in distant lesions because of metastasis. No significant difference was found in patient prognosis between the three groups. The difference in 3-year recurrence between the MIS and ORH groups was not statistically significant (MIS vs. ORH, 74.3 vs. 83.7%; log-rank P=0.253). In addition, there was no recurrence in patients with stage IB1 cervical cancer in the RARH group. LRH and RARH were superior to ORH with regard to surgical outcomes, such as estimated blood loss, and therefore may be considered a safe and feasible alternative to ORH. However, RARH would not be an appropriate surgical approach in patients with large tumors and parametrial invasion. In the future, the ideal indications for each surgical procedure should be reassessed, and the significance of the relationship between the difficulty of surgery, such as in cases of bulky tumor, parametrium invasion and vaginal invasion, and disease recurrence should be discussed. In conclusion, MIS could be safe and useful if proper case selection is performed.

Authors

Institutions

Publication Details

Journal
Molecular and Clinical Oncology
Published
2025-03-20
DOI
https://doi.org/10.3892/mco.2025.2838
Citations
1
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
2.06
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes and patterns of recurrence of robot‑assisted or laparoscopic radical hysterectomy in early‑stage cervical cancer

Hitomi Yamashita, Tomoka Ishibashi, Kentaro Nakayama, Masako Ishikawa et al.
1 citations
Molecular and Clinical Oncology
Endometrial and Cervical Cancer Treatments
2.06
article

Outcomes and patterns of recurrence of robot‑assisted or laparoscopic radical hysterectomy in early‑stage cervical cancer

Hitomi Yamashita, Tomoka Ishibashi, Kentaro Nakayama, Masako Ishikawa, Satoru Kyo, Seiya Sato, Sultana Razia
article en
1 citations

Abstract

The present study aimed to evaluate the surgical outcomes and prognosis of minimally invasive surgery (MIS), including robot-assisted radical hysterectomy (RARH) and laparoscopic radical hysterectomy (LRH), and open radical hysterectomy (ORH) for the treatment of early stage cervical cancer. A total of 43 patients were enrolled into the ORH group, 14 patients into the LRH group and 21 patients into the RARH group, and the patients were followed up for ≥3 years. Age, body mass index, International Federation of Gynecology and Obstetrics 2008 stage, histology, tumor size, lymphovascular space invasion, lymph node metastasis, number of dissected lymph nodes, operative duration, estimated blood loss, hospitalization duration and complications were reviewed. On follow-up, 16.3% of relapses (7/43) and 11.6% of deaths (5/43) occurred in the ORH group. In the LRH group, 14.3% of patients relapsed (2/14) and no deaths were reported; however, in the RARH group, 33.3% of patients relapsed and 9.5% died (2/21). In patients treated with RARH, >50% of recurrences occurred in distant lesions because of metastasis. No significant difference was found in patient prognosis between the three groups. The difference in 3-year recurrence between the MIS and ORH groups was not statistically significant (MIS vs. ORH, 74.3 vs. 83.7%; log-rank P=0.253). In addition, there was no recurrence in patients with stage IB1 cervical cancer in the RARH group. LRH and RARH were superior to ORH with regard to surgical outcomes, such as estimated blood loss, and therefore may be considered a safe and feasible alternative to ORH. However, RARH would not be an appropriate surgical approach in patients with large tumors and parametrial invasion. In the future, the ideal indications for each surgical procedure should be reassessed, and the significance of the relationship between the difficulty of surgery, such as in cases of bulky tumor, parametrium invasion and vaginal invasion, and disease recurrence should be discussed. In conclusion, MIS could be safe and useful if proper case selection is performed.

Molecular and Clinical OncologyVol. 22(5)
Shimane University (JP), Nagoya City University (JP)
Openalex Percentile: Top 17%
Endometrial and Cervical Cancer Treatments
2.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.